The effects of colchicine on hospitalized COVID-19 patients: A randomized, double-blind, placebo-controlled clinical trial
et al., Journal of Investigative Medicine,
Very late treatment (10 days from onset) RCT 110 patients in Iran, showing no significant difference in outcomes with colchicine. Colchicine 2mg loading dose followed by 0.5mg bid for 7 days.
risk of death, 7.3% lower, RR 0.93, p = 1.00, treatment 6 of 55 (10.9%), control 6 of 51 (11.8%), NNT 117.
risk of mechanical ventilation, 7.3% lower, RR 0.93, p = 1.00, treatment 6 of 55 (10.9%), control 6 of 51 (11.8%), NNT 117.
risk of ICU admission, 23.6% higher, RR 1.24, p = 0.63, treatment 12 of 55 (21.8%), control 9 of 51 (17.6%).
risk of no recovery, 27.9% lower, RR 0.72, p = 0.59, treatment 7 of 55 (12.7%), control 9 of 51 (17.6%), NNT 20, day 14.
risk of no recovery, 11.7% lower, RR 0.88, p = 0.69, treatment 20 of 55 (36.4%), control 21 of 51 (41.2%), NNT 21, day 7.
recovery time, 14.3% lower, relative time 0.86, p = 0.06, treatment 55, control 51.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Kasiri et al., 16 Jan 2023, Double Blind Randomized Controlled Trial, placebo-controlled, Iran, peer-reviewed, mean age 54.6, 6 authors, study period February 2021 - May 2021, average treatment delay 10.0 days, trial IRCT20190804044429N5
Abstract: Original Article
The effects of colchicine on hospitalized
COVID-19 patients: A randomized,
double-blind, placebo-controlled clinical
Journal of Investigative Medicine
2023, Vol. 00(0) 1–8
Ó 2023 American Federation for
Article reuse guidelines:
Hossein Kasiri1, Mobin Ghazaiean2, Nima Rouhani3,
Fahimeh Naderi-behdani1, Monireh Ghazaeian4,
and Robabeh Ghodssi-Ghassemabadi5
This study was designed to evaluate the effects of colchicine in the improvement of clinical outcomes of hospitalized
COVID-19 patients. This prospective, randomized, double-blind, placebo-controlled clinical trial was conducted on adult
patients (.18 years) with severe COVID-19. The included patients were randomly (1:1) assigned to the colchicine (2 mg
loading dose followed by 0.5 mg twice daily for 7 days) or placebo group. Both groups received remdesivir and interferon
beta-1b. The primary outcome of the study was to receive clinical response as ordinal scale of 1 or 2. Secondary outcomes
were hospital complications and 28-day mortality. Between February and May 2021, 110 patients were included and 106 of
them were analyzed. Baseline clinical characteristics and demographics were not significantly different. According to the ordinal scale, 30 patients in the control group (58.8%) responded to treatment within 7 days, while 35 patients (63.6%) in the colchicine group showed the same response (p = 0.61, odds ratio (OR) = 1.23, 95% CI [0.560–2.68]). On the 14th day, 87.3% of
the colchicine group (n = 48) and 82.4% of the control group (n = 42) responded (p = 0.48, OR = 1.47, 95% CI [0.50.3–4.29].
In addition, 28-day mortality, intensive care unit admission, and hospital duration were not different between the groups
(p = 0.99, 0.59, 0.06). Diarrhea and nausea were the major side effects dominant in the colchicine group. Colchicine showed
no beneficial effects on clinical improvement and hospital complications in patients with COVID-19. Moreover, in case of prescription, the safety concerns of colchicine, specially gastrointestinal side effects, should be taken into account.
Colchicine, COVID-19, efficacy
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.